ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).

Breast Cancer

Richard G. Margolese, MD

Richard G. Margolese, MD, Summarizes NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Richard G. Margolese, MD, of McGill University discusses the improvement in breast cancer-free interval with anastrozole vs tamoxifen in patients with DCIS undergoing lumpectomy plus radiotherapy (Abstract LBA500).

Breast Cancer

Nicholas C. Turner, MD, PhD

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (Abstract LBA502).

Global Cancer Care

Gynecologic Cancers

Eduardo Cazap, MD, PhD and James O. Armitage, MD

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Eduardo Cazap, MD, PhD, of the Latin American & Caribbean Society of Medical Oncology, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss oncology from an international point of view.

Lymphoma

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD, on Results of the GADOLIN Trial on Indolent Non-Hodgkin Lymphoma

James O. Armitage, MD, of the University of Nebraska Medical Center, and Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discuss a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Aug

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Richard G. Margolese, MD, Summarizes NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD, on Results of the GADOLIN Trial on Indolent Non-Hodgkin Lymphoma

Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma

When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology

Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer

AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer

WHO Calls for Action in New Status Report on Cancer